Prokineticins in Central and Peripheral Control of Human Reproduction
Overview
Authors
Affiliations
Prokineticin 1 (PROK1) and (PROK2), are two closely related proteins that were identified as the mammalian homologs of their two amphibian homologs, mamba intestinal toxin (MIT-1) and Bv8. PROKs activate two G-protein linked receptors (prokineticin receptor 1 and 2, PROKR1 and PROKR2). Both PROK1 and PROK2 have been found to regulate a stunning array of biological functions. In particular, PROKs stimulate gastrointestinal motility, thus accounting for their family name "prokineticins". PROK1 acts as a potent angiogenic mitogen, thus earning its other name, endocrine gland-derived vascular endothelial factor. In contrast, PROK2 signaling pathway has been shown to be a critical regulator of olfactory bulb morphogenesis and sexual maturation. During the last decade, strong evidences established the key roles of prokineticins in the control of human central and peripheral reproductive processes. PROKs act as main regulators of the physiological functions of the ovary, uterus, placenta, and testis, with marked dysfunctions in various pathological conditions such as recurrent pregnancy loss, and preeclampsia. PROKs have also been associated to the tumor development of some of these organs. In the central system, prokineticins control the migration of GnRH neurons, a key process that controls reproductive functions. Importantly, mutations in PROK2 and PROKR2 are associated to the development of Kallmann syndrome, with direct consequences on the reproductive system. This review describes the finely tuned actions of prokineticins in the control of the central and peripheral reproductive processes. Also, it discusses future research directions for the use of these cytokines as diagnostic markers for several reproductive diseases.
Antagonisation of Prokineticin Receptor-2 Attenuates Preeclampsia Symptoms.
Sergent F, Vaiman D, Raia-Barjat T, Younes H, Marquette C, Desseux M J Cell Mol Med. 2025; 29(2):e70346.
PMID: 39817714 PMC: 11736873. DOI: 10.1111/jcmm.70346.
Yilmaz N, Yildiz A Mol Biol Rep. 2024; 51(1):656.
PMID: 38740671 DOI: 10.1007/s11033-024-09604-4.
Ujvari D, Trouva A, Linden Hirschberg A, Vanky E BMJ Open. 2023; 13(11):e073619.
PMID: 37989369 PMC: 10668301. DOI: 10.1136/bmjopen-2023-073619.
Raia-Barjat T, Chauleur C, Collet C, Rancon F, Hoffmann P, Desseux M Sci Rep. 2023; 13(1):19921.
PMID: 37963927 PMC: 10645734. DOI: 10.1038/s41598-023-46883-6.
Therapeutic Potential of Targeting Prokineticin Receptors in Diseases.
Vincenzi M, Kremic A, Jouve A, Lattanzi R, Miele R, Benharouga M Pharmacol Rev. 2023; 75(6):1167-1199.
PMID: 37684054 PMC: 10595023. DOI: 10.1124/pharmrev.122.000801.